Saudi medical journal · 2026
COVID-19-Associated Rhabdomyolysis in Hospitalized Patients: Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Esquerdo-Serrano Paula, Otero-Rodriguez Silvia, Pinargote-Celorio Hector, Reus Sergio, Merino Esperanza, Ramos-Rincón José-Manuel
Аннотация
OBJECTIVES: To determine the frequency of rhabdomyolysis in patients hospitalized with COVID-19 and to characterize their clinical features and outcomes.
METHODS: All adults admitted to the hospital were included in this single-center retrospective cohort study with COVID-19 at a tertiary care institution in Alicante, Spain, between March 2020 and March 2024. A creatine kinase (CK) threshold of 1000 U/L or higher was used to define rhabdomyolysis. Demographic, clinical, laboratory, treatment, and outcome data were collected. Patients with and without rhabdomyolysis were compared, and factors associated with in-hospital mortality (IHM) were analyzed.
RESULTS: Among 7,590 hospitalized COVID-19 patients, 20 developed rhabdomyolyses (cumulative incidence 0.26%; 95% CI 0.170.41). Most affected patients were male (85%), and male sex demonstrated an independent relationship with rhabdomyolysis (adjusted OR 4.35; 95% CI 1.2714.94). Acute kidney injury was observed in 60% of patients, and 15% required hemodialysis. IHM was markedly higher among patients with rhabdomyolysis than in those without (35% vs. 11.5%) (adjusted OR 4.24; 95% CI 1.4812.10).
CONCLUSION: Rhabdomyolysis was an uncommon but severe complication of COVID-19, predominantly affecting men and frequently inked to acute kidney failure and high IHM.
METHODS: All adults admitted to the hospital were included in this single-center retrospective cohort study with COVID-19 at a tertiary care institution in Alicante, Spain, between March 2020 and March 2024. A creatine kinase (CK) threshold of 1000 U/L or higher was used to define rhabdomyolysis. Demographic, clinical, laboratory, treatment, and outcome data were collected. Patients with and without rhabdomyolysis were compared, and factors associated with in-hospital mortality (IHM) were analyzed.
RESULTS: Among 7,590 hospitalized COVID-19 patients, 20 developed rhabdomyolyses (cumulative incidence 0.26%; 95% CI 0.170.41). Most affected patients were male (85%), and male sex demonstrated an independent relationship with rhabdomyolysis (adjusted OR 4.35; 95% CI 1.2714.94). Acute kidney injury was observed in 60% of patients, and 15% required hemodialysis. IHM was markedly higher among patients with rhabdomyolysis than in those without (35% vs. 11.5%) (adjusted OR 4.24; 95% CI 1.4812.10).
CONCLUSION: Rhabdomyolysis was an uncommon but severe complication of COVID-19, predominantly affecting men and frequently inked to acute kidney failure and high IHM.